True Diagnostics has obtained CE mark approval for its TrueDX Platform and thyroid stimulating hormone (TSH) test.
By using a finger prick of blood on TrueDX Platform, doctors can determine if a patient suffers from a hypoactive thyroid.
TrueDX Platform enables doctors and patients to gain access to diagnosis in minutes and to create an effective treatment plan.
True Diagnostics president and CEO Jerry Lee said with the CE mark, the company has laid the foundation to begin standardizing a full range of diagnostic and monitoring tests that will provide instant results to doctors and patients and demand little training.
"With distribution partners already lined up and more coming soon, we expect initial shipments to Europe to begin within 60 days," Lee added.